Targeting cancer stem cells through L1CAM suppresses glioma growth
- PMID: 18676824
- PMCID: PMC2739001
- DOI: 10.1158/0008-5472.CAN-08-1079
Targeting cancer stem cells through L1CAM suppresses glioma growth
Abstract
Malignant gliomas are lethal cancers that display striking cellular heterogeneity. A highly tumorigenic glioma tumor subpopulation, termed cancer stem cells or tumor-initiating cells, promotes therapeutic resistance and tumor angiogenesis. Therefore, targeting cancer stem cells may improve patient survival. We interrogated the role of a neuronal cell adhesion molecule, L1CAM, in glioma stem cells as L1CAM regulates brain development and is expressed in gliomas. L1CAM(+) and CD133(+) cells cosegregated in gliomas, and levels of L1CAM were higher in CD133(+) glioma cells than normal neural progenitors. Targeting L1CAM using lentiviral-mediated short hairpin RNA (shRNA) interference in CD133(+) glioma cells potently disrupted neurosphere formation, induced apoptosis, and inhibited growth specifically in glioma stem cells. We identified a novel mechanism for L1CAM regulation of cell survival as L1CAM knockdown decreased expression of the basic helix-loop-helix transcription factor Olig2 and up-regulated the p21(WAF1/CIP1) tumor suppressor in CD133(+) glioma cells. To determine if targeting L1CAM was sufficient to reduce glioma stem cell tumor growth in vivo, we targeted L1CAM in glioma cells before injection into immunocompromised mice or directly in established tumors. In each glioma xenograft model, shRNA targeting of L1CAM expression in vivo suppressed tumor growth and increased the survival of tumor-bearing animals. Together, these data show that L1CAM is required for maintaining the growth and survival of CD133(+) glioma cells both in vitro and in vivo, and L1CAM may represent a cancer stem cell-specific therapeutic target for improving the treatment of malignant gliomas and other brain tumors.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2739001/bin/nihms-123195-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2739001/bin/nihms-123195-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2739001/bin/nihms-123195-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/2739001/bin/nihms-123195-f0004.gif)
Similar articles
-
The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.J Neurooncol. 2011 Nov;105(2):149-57. doi: 10.1007/s11060-011-0572-y. Epub 2011 Apr 11. J Neurooncol. 2011. PMID: 21479962
-
Biology of glioma cancer stem cells.Mol Cells. 2009 Jul 31;28(1):7-12. doi: 10.1007/s10059-009-0111-2. Epub 2009 Jul 20. Mol Cells. 2009. PMID: 19655094 Review.
-
c-Myc is required for maintenance of glioma cancer stem cells.PLoS One. 2008;3(11):e3769. doi: 10.1371/journal.pone.0003769. Epub 2008 Nov 20. PLoS One. 2008. PMID: 19020659 Free PMC article.
-
Stem cell markers in gliomas.Neurochem Res. 2008 Dec;33(12):2407-15. doi: 10.1007/s11064-008-9723-8. Epub 2008 May 21. Neurochem Res. 2008. PMID: 18493853 Review.
-
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5. doi: 10.1227/01.neu.0000316019.28421.95. Neurosurgery. 2008. PMID: 18382330
Cited by
-
Mechanisms of angiogenesis in tumour.Front Oncol. 2024 Mar 25;14:1359069. doi: 10.3389/fonc.2024.1359069. eCollection 2024. Front Oncol. 2024. PMID: 38590656 Free PMC article. Review.
-
Progress in Glioma Stem Cell Research.Cancers (Basel). 2023 Dec 24;16(1):102. doi: 10.3390/cancers16010102. Cancers (Basel). 2023. PMID: 38201528 Free PMC article. Review.
-
Inhibitor of Wnt receptor 1 suppresses the effects of Wnt1, Wnt3a and β‑catenin on the proliferation and migration of C6 GSCs induced by low‑dose radiation.Oncol Rep. 2024 Feb;51(2):22. doi: 10.3892/or.2023.8681. Epub 2023 Dec 15. Oncol Rep. 2024. PMID: 38099414 Free PMC article.
-
Proteomics reveals differentially regulated pathways when comparing grade 2 and 4 astrocytomas.PLoS One. 2023 Nov 15;18(11):e0290087. doi: 10.1371/journal.pone.0290087. eCollection 2023. PLoS One. 2023. PMID: 37967105 Free PMC article.
-
Identification of glioblastoma stem cell-associated lncRNAs using single-cell RNA sequencing datasets.Stem Cell Reports. 2023 Nov 14;18(11):2056-2070. doi: 10.1016/j.stemcr.2023.10.004. Epub 2023 Nov 2. Stem Cell Reports. 2023. PMID: 37922916 Free PMC article.
References
-
- Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8. - PubMed
-
- Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–21. - PubMed
-
- Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. - PubMed
-
- Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- NS054276/NS/NINDS NIH HHS/United States
- R01 CA116659/CA/NCI NIH HHS/United States
- R01 NS054276-03/NS/NINDS NIH HHS/United States
- CA129958/CA/NCI NIH HHS/United States
- CA116659/CA/NCI NIH HHS/United States
- K02 NS047409-04/NS/NINDS NIH HHS/United States
- R01 CA129958/CA/NCI NIH HHS/United States
- R01 CA116659-03/CA/NCI NIH HHS/United States
- K02 NS047409/NS/NINDS NIH HHS/United States
- NS047409/NS/NINDS NIH HHS/United States
- R01 NS054276/NS/NINDS NIH HHS/United States
- R01 CA129958-01A1/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials